Neuren Media and Analyst Coverage, page-1308

Interesting that Davis suggests that Acadia may be considering the acquisition of other rare disease assets.

With a market cap of US$2.5 billion and net equity of only US$516 million it is hardly in a position to make an offer for Neuren, particularly if the NEU BOD is thinking in terms of a necessary valuation around the Reata US$7.3 billion (AU$11.1 billion) level.

There is a sensible compromise, though, and that would be the purchase by Acadia of a single rare disease asset from Neuren.

Taking Angelman as an example, the Neuren BOD might consider that the best way to obtain value from the Angelman program, and for its earliest availability to sufferers of the disease, would be by a clean sale of that asset to Acadia (or another interested party) for its development.

This could be mutually beneficial to both companies, and to Angelman patients, with Acadia already familiar with NNZ-2591 through its partnered application to Rett and Fragile-X development.

Just a thought.